Senseonics Launches Automated Insulin Dosing System with 1-Year CGM

Why It Matters

The partnership gives Senseonics a unique market edge with a long‑wear CGM, potentially reshaping automated diabetes care and driving significant revenue upside.

Key Takeaways

• Eversense 365 integrates with Sequel twiist AID system.
• One‑year implant CGM offers longer wear than 15‑day patches.
• Launch delayed to Q4 2025, early commercial use begun.
• Senseonics sales rose 57% to $35.2 M in 2025.
• Pump capacity may limit early 2026 growth.

Pulse Analysis

The integration of Senseonics’ Eversense 365 implantable sensor with Sequel’s twiist automated insulin‑delivery pump introduces a paradigm shift in continuous glucose monitoring. While most market leaders rely on disposable patches that require replacement every two weeks, the year‑long CGM eliminates frequent sensor changes, reducing patient burden and potentially improving adherence. This durability also opens new revenue streams for manufacturers, as the longer sensor lifecycle can justify premium pricing and differentiate the offering in a crowded AID landscape.

Competitive pressure intensifies as Abbott and Dexcom continue to pair their short‑wear sensors with established pump makers. However, the supply‑side challenges highlighted by Senseonics—particularly the need to scale pump production—underscore a critical bottleneck that could affect market penetration. Early adopters have signaled strong interest, but limited pump availability may constrain sales momentum through the first half of 2026. Investors will watch closely how quickly Sequel can ramp up manufacturing to meet demand, a factor that could determine whether the partnership translates into sustained top‑line growth.

Beyond immediate commercial implications, the year‑long CGM integration signals broader trends in diabetes technology. Longer‑lasting sensors enable richer data sets for algorithmic insulin dosing, fostering more precise glucose control and reducing hypoglycemia risk. As healthcare systems prioritize value‑based care, solutions that combine durability with automation are poised to become preferred options for both patients and payers. Looking ahead, the success of this collaboration could spur further innovation, encouraging other manufacturers to explore implantable sensors and solidify the role of closed‑loop systems in chronic disease management.